Compare Gilead Sciences, Inc. (GILD) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares MBS ETF — how do they compare? Gilead Sciences, Inc. trades at $134.82 (market cap $163.51B), while iShares MBS ETF trades at $93.77. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares MBS ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| GILD | MBB | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $96.91 |
52-Week Low | $108.22 | $92.62 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MBB (iShares MBS ETF) trades at $93.77, up 0.1% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key support/resistance clustered around $94. Recent institutional activity is mixed, with some firms increasing positions while others reduced holdings. The fund provides exposure to mortgage-backed securities and pays regular dividends, with recent distributions of $0.33-0.34 per share.
The ETF faces headwinds from interest rate sensitivity and housing market volatility, though its 4% yield provides income appeal. Technical weakness suggests near-term pressure, while institutional interest remains divided. Mortgage market stability and Fed policy will be key drivers for performance ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
